Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection

Launched by LOMA LINDA UNIVERSITY · Oct 18, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict acute rejection in kidney transplant patients, which is when the body’s immune system attacks the transplanted kidney. Researchers are looking at two main factors: donor-derived cell-free DNA (dd-cfDNA), which can indicate if rejection is likely to happen, and a specific type of immune cell called regulatory T cells (Tregs) that help keep the immune response in check. By measuring these two factors in 150 kidney transplant recipients during the first six months after their transplant, the goal is to better identify those at risk for rejection early on and adjust their medications accordingly to improve kidney function in the long run.

To be eligible for this trial, participants need to be adult kidney transplant candidates or recipients aged 18 and older. Those with multi-organ transplants or certain health conditions, like HIV or hepatitis C, will not be included. If you participate, you will have your blood tested at scheduled times to measure the levels of dd-cfDNA and Tregs. The researchers will then analyze this information to see if it can accurately predict both acute rejection and how well the transplanted kidney will function over the next year. This research could lead to more personalized care for kidney transplant patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult kidney transplant candidates/recipients
• Exclusion Criteria:
• • Age less than 18
• • Multi-organ transplants
• • Kidney transplant candidates/recipients with HIV
• • Kidney transplant candidates/recipients with HCV